Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Zucca E, et al. Among authors: ghielmini m. Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17. Blood. 2019. PMID: 31101627 Free article. Clinical Trial.
How I treat mantle cell lymphoma.
Ghielmini M, Zucca E. Ghielmini M, et al. Blood. 2009 Aug 20;114(8):1469-76. doi: 10.1182/blood-2009-02-179739. Epub 2009 Jun 25. Blood. 2009. PMID: 19556426 Free article. Review.
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Taverna C, et al. Among authors: ghielmini m. J Clin Oncol. 2016 Feb 10;34(5):495-500. doi: 10.1200/JCO.2015.61.3968. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712227 Free PMC article. Clinical Trial.
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).
Moccia AA, Schär S, Hayoz S, Pirosa MC, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: ghielmini m. Br J Haematol. 2021 Mar;192(6):1031-1034. doi: 10.1111/bjh.17045. Epub 2020 Aug 17. Br J Haematol. 2021. PMID: 32805081 Free article. Clinical Trial.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: ghielmini m. Blood Adv. 2020 Dec 8;4(23):5951-5957. doi: 10.1182/bloodadvances.2020002858. Blood Adv. 2020. PMID: 33275769 Free PMC article. Clinical Trial.
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Ghielmini M, et al. Blood. 2004 Jun 15;103(12):4416-23. doi: 10.1182/blood-2003-10-3411. Epub 2004 Feb 19. Blood. 2004. PMID: 14976046 Free article. Clinical Trial.
Open questions in the management of mantle cell lymphoma.
Li ZM, Zucca E, Ghielmini M. Li ZM, et al. Among authors: ghielmini m. Cancer Treat Rev. 2013 Oct;39(6):602-9. doi: 10.1016/j.ctrv.2012.12.013. Epub 2013 Feb 13. Cancer Treat Rev. 2013. PMID: 23415066 Review.
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).
Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M. Voegeli M, et al. Among authors: ghielmini m. Hematol Oncol. 2017 Dec;35(4):576-583. doi: 10.1002/hon.2348. Epub 2016 Sep 28. Hematol Oncol. 2017. PMID: 27677906 Clinical Trial.
129 results